Home
/
Arcutis Biotherapeutics, Inc.
/
Financials
/
Quarterly
Arcutis Biotherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Arcutis Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$99.22M
Oct 28, 2025
Q2
2025
Jun 30, 2025
$81.50M
Aug 6, 2025
Q1
2025
Mar 31, 2025
$65.85M
May 6, 2025
Q3
2025
Sep 30, 2024
$44.76M
Oct 28, 2025
Q2
2025
Jun 30, 2024
$30.86M
Aug 6, 2025
Q1
2025
Mar 31, 2024
$49.57M
May 6, 2025
Q3
2024
Sep 30, 2023
$38.11M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$5.19M
Aug 14, 2024
Q1
2024
Mar 31, 2023
$2.78M
May 14, 2024
Q2
2023
Jun 30, 2022
$0
Aug 8, 2023
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$7.41M
Oct 28, 2025
Q3
2025
Jun 30, 2025
($15.89M)
Oct 28, 2025
Q2
2025
Jun 30, 2025
($15.89M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($25.06M)
May 6, 2025
Q2
2025
Mar 31, 2025
($25.06M)
Aug 6, 2025
Q3
2025
Mar 31, 2025
($25.06M)
Oct 28, 2025
Q3
2025
Sep 30, 2024
($41.54M)
Oct 28, 2025
Q3
2025
Jun 30, 2024
($52.33M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($52.33M)
Aug 6, 2025
Q2
2025
Mar 31, 2024
($35.38M)
Aug 6, 2025
Q3
2025
Mar 31, 2024
($35.38M)
Oct 28, 2025
Q1
2025
Mar 31, 2024
($35.38M)
May 6, 2025
Q3
2024
Sep 30, 2023
($44.77M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($70.99M)
Aug 14, 2024
Q3
2024
Jun 30, 2023
($70.99M)
Nov 6, 2024
Q2
2024
Mar 31, 2023
($80.10M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($80.10M)
May 14, 2024
Q3
2024
Mar 31, 2023
($80.10M)
Nov 6, 2024
Q3
2023
Sep 30, 2022
($107.71M)
Nov 3, 2023
Q3
2023
Jun 30, 2022
($67.41M)
Nov 3, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.53M
Oct 28, 2025
Q2
2025
Jun 30, 2025
($14.61M)
Aug 6, 2025
Q1
2025
Mar 31, 2025
($24.53M)
May 6, 2025
Q3
2025
Sep 30, 2024
($39.07M)
Oct 28, 2025
Q2
2025
Jun 30, 2024
($50.08M)
Aug 6, 2025
Q1
2025
Mar 31, 2024
($31.62M)
May 6, 2025
Q3
2024
Sep 30, 2023
($36.90M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($66.76M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($76.27M)
May 14, 2024
Q3
2023
Sep 30, 2022
($104.75M)
Nov 3, 2023
Q2
2023
Jun 30, 2022
($65.83M)
Aug 8, 2023
Q1
2023
Mar 31, 2022
($62.63M)
May 9, 2023
Q3
2022
Sep 30, 2021
($57.08M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($42.08M)
Aug 4, 2022
Q1
2022
Mar 31, 2021
($36.09M)
May 5, 2022
Q3
2021
Sep 30, 2020
($38.30M)
Nov 4, 2021
Q2
2021
Jun 30, 2020
($35.63M)
Aug 5, 2021
Q1
2021
Mar 31, 2020
($28.65M)
May 6, 2021
Q3
2020
Sep 30, 2019
($14.65M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($8.54M)
Aug 11, 2020